Drug Profile
KiroVAX 003
Alternative Names: CT-003; KiroVAX003; TAPA loaded DC vaccine - KiroVAX-003; TAPA loaded dendritic cell vaccine - KiroVAX-003; TAPA pulsed dendritic cell vaccine - KiroVAX-003; TAPA-pulsed DC vaccine - KiroVAX-003; Tumour associated peptide antigen loaded DC vaccine-KiroVAX-003; Tumour associated peptide antigen loaded dendritic cell vaccine - KiroVAX-003; Tumour associated peptide antigen pulsed DC vaccine - KiroVAX-003; Tumour associated peptide antigen pulsed dendritic cell vaccine - KiroVAX-003Latest Information Update: 30 Sep 2020
Price :
$50
*
At a glance
- Originator Kiromic
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 30 Sep 2020 No development reported - Phase-I/II for Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (Intradermal)
- 28 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT02224599)
- 01 Sep 2014 Phase-I clinical trials in Solid tumours in USA (Intradermal)